EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma

Qian Liang, Miaomiao Gong, Jing-Hua Zou, Ming-Yu Luo, Lu-Lu Jiang, Cheng Wang, Ning-Xiang Shen, Mo-Cong Zhang, Lu Xu, Hui-Min Lei, Ke-Ren Zhang, Rui Zhang und 5 weitere

Drug Resistance Updates · 2023-05 · 68 · 100957

DOI: 10.1016/j.drup.2023.100957 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2023-05. Verfasst von Qian Liang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Chemical Biology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao…. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Postdoctoral Science Foundation, Science and Technology Commission of Shanghai Municipality, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to epidermal growth factor receptor (EGFR) inhibitors, from the first-generation erlotinib to the third generation osimertinib, is a clinical challenge in the treatment of patients with EGFR-mutant lung adenocarcinoma. Our previous work found that a novel allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1), HKB99, restrains erlotinib resistance in lung adenocarcinoma cells. However, the role of HKB99 in osimertinib resistance and its underlying molecular mechanism remains to be elucidated. Herein, we found that IL-6/JAK2/STAT3 signaling pathway is aberrantly activated in both erlotinib and osimertinib resistant cells. Importantly, HKB99 significantly blocks the interaction of PGAM1 with JAK2 and STAT3 via the allosteric sites of PGAM1, which leads to inactivation of JAK2/STAT3 and thereby disrupts IL-6/JAK2/STAT3 signaling pathway. Consequently, HKB99 remarkably restores EGFR inhibitor sensitivity and exerts synergistic tumoricidal effect. Additionally, HKB99 alone or in combination with osimertinib down-regulated the level of p-STAT3 in xenograft tumor models. Collectively, this study identifies PGAM1 as a key regulator in IL-6/JAK2/STAT3 axis in the development of resistance to EGFR inhibitors, which could serve as a therapeutic target in lung adenocarcinoma with acquired resistance to EGFR inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungHumansErlotinib HydrochlorideInterleukin-6Phosphoglycerate MutaseDrug Resistance, NeoplasmErbB ReceptorsSignal TransductionProtein Kinase InhibitorsMutationCell Line, TumorJanus Kinase 2AnthracenesBenzenesulfonamidesAcrylamidesAniline CompoundsIndolesPyrimidinesSTAT3 Transcription Factor

Stichwörter der Autor:innen

Allosteric inhibitorEGFR inhibitor resistanceJAK2/STAT3 signaling pathwayLung adenocarcinomaPhosphoglycerate mutase 1

Substanzen

Erlotinib HydrochlorideInterleukin-6Phosphoglycerate MutaseErbB ReceptorsProtein Kinase InhibitorsJanus Kinase 2HKB99AnthracenesBenzenesulfonamidesosimertinib

Autor:innen und Institutionen

  • Department of Pharmacology and Chemical Biology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Collabora…
  • Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China.
  • State Key Laboratory of Oncogenes and Related Genes, Department of Thoracic Surgery, Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
  • Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. El…
  • Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China. Electronic address: zhoulu@fudan.edu.cn.

Förderung

  • China Postdoctoral Science Foundation
  • Science and Technology Commission of Shanghai Municipality
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • School of Medicine, Shanghai Jiao Tong University

Zitieren

APA

Liang, Q., Gong, M., Zou, J. H., Luo, M. Y., Jiang, L. L., Wang, C., Shen, N. X., Zhang, M. C., Xu, L., Lei, H. M., Zhang, K. R., Zhang, R., Zhuang, G., Zhu, L., Chen, H. Z., Zhou, L., & Shen, Y. (2023). A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma. Drug Resistance Updates, 68, 100957. https://doi.org/10.1016/j.drup.2023.100957

Vancouver

Liang Q, Gong M, Zou JH, Luo MY, Jiang LL, Wang C, et al. A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma. Drug Resistance Updates. 2023;68:100957. doi:10.1016/j.drup.2023.100957

BibTeX
@article{Liang2023,
  author = {Liang, Qian and Gong, Miaomiao and Zou, Jing-Hua and Luo, Ming-Yu and Jiang, Lu-Lu and Wang, Cheng and Shen, Ning-Xiang and Zhang, Mo-Cong and Xu, Lu and Lei, Hui-Min and Zhang, Ke-Ren and Zhang, Rui and Zhuang, Guanglei and Zhu, Liang and Chen, Hong-Zhuan and Zhou, Lu and Shen, Ying},
  title = {A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma},
  journal = {Drug Resistance Updates},
  year = {2023},
  volume = {68},
  pages = {100957},
  doi = {10.1016/j.drup.2023.100957}
}
Kostenlos starten →